Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib: Evaluation of the Safety and as a Secondary End Point the Efficacy for Two Doses of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction

NCT02945449 is registered in ClinicalTrials.gov with Sophia Al-Adwan as lead sponsor.

NCT NCT02945449
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02945449 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib: Evaluation of the Safety and as a Secondary End Point the Efficacy for Two Doses of Wharton Jelly Stem Cells for the Treatment of Diabetic Erectile Dysfunction
Lead sponsor
Sophia Al-Adwan
Phase
Phase 1
Overall status
Completed
Start date
January 4, 2017
Completion date
November 30, 2018
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction associated with type 2 diabetes mellitus